Bristol-Myers Squibb Company (BMY)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 76.91 |
| Open | 76.94 |
| Bid | 77.74 x 900 |
| Ask | 79.00 x 2900 |
| Day's range | 76.81 - 78.43 |
| 52-week range | 53.22 - 78.43 |
| Volume | |
| Avg. volume | 15,525,191 |
| Market cap | 173.62B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings date | 27 Apr 2022 - 02 May 2022 |
| Forward dividend & yield | 2.16 (2.85%) |
| Ex-dividend date | 31 Mar 2022 |
| 1y target est | 79.16 |
- Zacks
Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
- Business Wire
Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., May 16, 2022--BMS Provides Update on CheckMate -901 Trial
- Zacks
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
© 2022 Yahoo. All rights reserved.
